New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
08:13 EDTMACKMerrimack MM-141 preclinical study published in Molecular Cancer Therapeutics
Merrimack Pharmaceuticals announced that the manuscript "MM-141, an IGF-1R- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-1R Inhibitors" has been published in Molecular Cancer Therapeutics and selected for the Highlights section in the current issue . This publication describes the preclinical development of Merrimack's MM-141, a novel bispecific tetravalent antibody that binds to IGF-1R and ErbB3 receptors. With this mechanism, MM-141 is able to inhibit oncogenic signaling through the PI3K/AKT/mTOR pathway, which is a driving force behind cell growth. MM-141 recently completed the monotherapy portion of a Phase 1 study in the United States and Europe. It is currently being investigated in a Phase 1 combination study and is expected to enter Phase 2 development in 2014. IGF-1R, the receptor activated by insulin-like growth factor 1, has the ability to induce cellular growth and proliferation. Thus, it has been implicated in promoting resistance to both chemotherapies and targeted therapies. However, the effectiveness of current IGF-1R inhibitors in the clinic has been limited, as cancer cells have the ability to develop resistance to therapies by signaling through alternative pathways. Through a systems biology-based methodology, Merrimack researchers have found that cancer cells can develop resistance to IGF-1R that is mediated through ErbB3. Therefore, dual inhibition of IGF-1R and ErbB3 pathways would be necessary to block the PI3K/AKT/mTOR pathway, resulting in the arrest of tumor cell growth. In preclinical in vitro and in vivo models, MM-141 was more active than a combination of anti-ErbB3 and anti-IGF-1R monoclonal antibodies. MM-141 was able to inhibit PI3K/AKT/mTOR signaling and potentiated the activity of cytotoxic and targeted therapies, supporting its ongoing clinical development.
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
05:20 EDTMACKPharmaEngine, Merrimack receive FDA fast track designation for MM-398
PharmaEngine and its partner Merrimack Pharmaceuticals (MACK) announced that MM-398 has been granted the Fast Track designation by the FDA for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Merrimack expects to begin the NDA submission in 2014.
November 19, 2014
09:16 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
08:07 EDTMACKMerrimack receives FDA fast track designation for MM-398
Subscribe for More Information
November 18, 2014
07:20 EDTMACKEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 13, 2014
09:15 EDTMACKMerrimack to present advances on targeted cancer molecules
Merrimack Pharmaceuticals announced that it will present research on three of its therapeutic candidates at the 2014 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 18-21. Data will be shared in four poster sessions. Presentations will include results from a clinical study using ferumoxytol as a magnetic resonance imaging agent and its ability to predict tumor response to MM-398, preclinical and clinical research on MM-151 and an initial preclinical study of MM-131, a novel bispecific antibody targeting the c-Met tumor signaling pathway.
November 11, 2014
08:05 EDTMACKMerrimack shares should be bought on weakness, says Oppenheimer
After Merrimack announced a delay of about one quarter for the NDA submission of its MM-398, Oppenheimer's concern about the issue is limited. The firm says that the FDA appears to be interested in ensuring that MM-398 has extended nanoparticle stability, but does not appear to have identified a material deficit in the company's chemistry, manufacturing, and controls. Oppenheimer keeps an $11 price target and Outperform rating on Merrimack.
November 10, 2014
16:09 EDTMACKMerrimack reports Q3 EPS (27c), consensus (12c)
Subscribe for More Information
November 6, 2014
09:10 EDTMACKMerrimack initiates MM-398 Phase 1 clinical study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use